- recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The MOMENTUM Study is tracking how a new type of advanced radiotherapy, called MR-Linac, works for people with different cancers. It aims to see if this treatment improves survival, controls cancer better, and enhances quality of life by using highly precise radiation guidance.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
HTL0039732 in Participants With Advanced Solid Tumours
This study is testing a new drug, HTL0039732, alone and with another cancer medicine, atezolizumab. It's for people with advanced solid tumours, aiming to see if blocking certain signals can help the immune system fight cancer. The goal is to find the right dose and see how well it works.
United Kingdom - recruiting
The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD)
This study looks at how treatments for head and neck cancer, like radiotherapy and chemotherapy, affect hearing. We want to understand why some people experience hearing loss and ringing in their ears (tinnitus), and find ways to protect hearing better during treatment.
United Kingdom - active not recruitingPHASE2
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
This study is testing a new drug, disitamab vedotin, for certain advanced cancers like head and neck, lung, ovarian, and endometrial cancer. It's for people whose cancer has a marker called HER2 and has already been treated. The study wants to see how well the new drug works and if it's safe.
United States · Australia · Canada - active not recruiting
ENHANCE - Evaluating the Implementation of Head and Neck Cancer E-health
This study looks at how a smartphone app helps people in London with head and neck cancer manage their health during treatment. It checks if the app is easy to use and helpful, and finds ways to improve digital cancer care across the UK.
United Kingdom - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - active not recruitingPHASE3
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
This study is looking at a new way to treat advanced head and neck cancer. It combines a drug called pembrolizumab with surgery and radiotherapy, aiming to improve how long people live without the cancer returning compared to standard treatment.
United States · Argentina · Australia